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Letter to the Editor
Preliminary  guidelines  of  the Brazilian  Society  of
Rheumatology for  evaluation  and  treatment  of
tuberculosis latent  infection  in patients  with
rheumatoid arthritis,  in  face of unavailability  of the
tuberculin skin  test
Orientac¸ões  preliminares  da  Sociedade  Brasileira  de  Reumatologia
para  avaliac¸ão  e  tratamento  da  tuberculose  infecc¸ão latente  em
pacientes  com  artrite  reumatoide  na  indisponibilidade  do  teste
tuberculínico
Introduction
The detection and treatment of tuberculosis latent infection
(TBLI) in individuals with increased risk of progression to
tuberculosis (TB) disease are strategies recommended by the
World Health Organization to control this disease. The tuber-
culin test, which uses PPD (puriﬁed protein derivative), is a
procedure widely incorporated to the clinical practice for the
diagnosis of TBLI. Patients with rheumatoid arthritis are in
increased risk for the development of active TB, particularly
when treated with biological agents of TNF- inhibitor class.
The 2012 Consensus of The Brazilian Society of Rheumatology
(BSR) for treating rheumatoid arthritis recommends the use of
screening procedures and, where indicated, the treatment of
TBLI in every patient candidate to use some biological agent.
In addition to the evaluation of the epidemiological risk,
this screening includes performing chest radiography and a
tuberculin test. After the exclusion of TB disease, the treat-
ment of TBLI consists of isoniazid at a dose of 5–10 mg/kg/day
(with a maximum of 300 mg/day) for 6 months. This treatment
is indicated in patients with tuberculin test ≥5 mm,  positivity
for IGRA (interferon- release assays), radiographic ﬁndings
consistent with prior TB, or close contact with a TB case. The
treatment of TBLI (chemoprophylaxis) should be established
at least one month before introducing the biological agent;
however, exceptionally and when the symptomatic urgency
of the situation demands it, both drugs may be initiated con-
comitantly.In September 2014, the Ministry of Health, through
the General Coordination of the National Program for
Tuberculosis Control, published a note informing on the
difﬁculties to acquire PPD, thanks to its unavailability in
the international market, which should result in shortages
of the Brazilian health system, still without any predic-
tion for resumption of its distribution (information note
n◦ 8/CGPNCT/DEVEP/SVS/MS, of September 10, 2014). The
unavailability of the tuberculin test has already been effec-
tively felt in our health care network. Considering that the
current situation require a quick attitude in order to guide
clinical practice, the Arthritis Rheumatoid Committee of BSR
decided to disclose the following preliminary guidelines,
which were developed by expert consensus. The Committee
suggests a consultation of selected references, which extend
the discussions here developed.1–12
The  recommendations  for  an  evaluation  and  treatment  of
TBLI in  patients  with  rheumatoid  arthritis  are  different
when  using  TNF-˛  inhibitors  and  biological  agents  with
other  mechanisms  of  action?
There is a difference in the risk of TB reactivation when
using TNF- inhibitors, which represent an increased risk
– especially in the case of monoclonal antibodies, in com-
parison with other not-TNF--inhibitor biologicals. However,
the 2012 BSR Consensus for the treatment of rheumatoid
arthritis, considering the high prevalence of TB in Brazil, and
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lso considering reports of disease reactivation during the
mmunosuppressive treatment, recommended TBLI screening
hen using any biological DMARDs.
Inserts of some of the not-TNF-  inhibitor biologicals, such
s tocilizumab and abatacept, also recommend carrying out a
BLI screening prior to the use of the drug. Thus, considering
lso possible medico-legal implications, at present BSR prefer
o keep the same recommendations for evaluation and treat-
ent of TBLI, in the case of use of any biological DMARDs for
reatment of rheumatoid arthritis. These recommendations
lso apply to the use of corticosteroids at a dose equivalent to
rednisone ≥15 mg/day for more  than 30 days in individuals
lder than 65 years.
hat  should  be  regarded  as  a  positive  epidemiology  for
uberculosis?
ontact with a bacilliferous case of pulmonary or respiratory
B is the key epidemiological factor. The risk of acquiring
BLI by contacting a bacilliferous patient is increased by con-
itions such as household contact (especially among those
ho  share the same bedroom); longer exposure time; expo-
ure in places with poor ventilation; cavitation revealed in
 chest X-ray from the index case; positive direct bacil-
oscopy, and greater amount of bacilli in the index case
putum. Patients exposed to coexistence situations with a
igh disease burden, namely, health professionals, prison
nmates, residents of nursing homes or hostels, and injectable
rug users, are deﬁned as people in greater epidemiological
isk.
The risk of developing TB disease is higher in the ﬁrst
wo years after infection. Contacts of bacilliferous individu-
ls are at increased risk of developing TB disease, when in
ituations of extreme age (≤10 years or >60 years), immuno-
uppression, household exposure, and exposure to patients
ith positive bacilloscopy or sputum culture. Tuberculin test
5 mm is also a risk factor for developing TB disease in
ontacts. The main clinical condition associated with pro-
ression from TBLI to TB disease is co-infection with HIV,
articularly when CD4+ T cells ≤200/mm3. Other medical
onditions meaning risk for progression from TBLI to TB dis-
ase are: use of a TNF- inhibitor, diabetes mellitus, chronic
enal failure on dialysis, malignant neoplasms, immunosup-
ression associated with organ transplantation, malnutrition,
hanges in chest X-ray – especially ﬁbrotic lesions in upper
reas (with or without calciﬁed nodules or pleural thickening)
 suggestive of sequel of a previously untreated pulmonary
B.
atients  with  rheumatoid  arthritis,  when  in  use  of
iopharmaceuticals  and  with  a  positive  history  of  contact
ith a  pulmonary  TB  case,  should  be  treated  for  TBLI
ithout  a  tuberculin  test?
es. The recommendation is to proceed with the TBLI treat-
ent without the tuberculin test in contacts of pulmonary TB
ases, when using TNF- inhibitors. TNF- inhibitor users with
 suggestive X-ray of untreated pulmonary TB sequel should
lso be treated for TBLI, regardless of the tuberculin test. It 5;5 5(4):390–393 391
is believed that, in these cases, the beneﬁt of preventing TB
overcomes the risks of a preventive treatment.
When  using  biopharmaceuticals,  patients  with
rheumatoid  arthritis  with  no  history  of  contact  with  a
case of  pulmonary  TB  should  receive  treatment  for  TBLI
without  a  tuberculin  test?
A negative history of contact does not exclude TBLI. In
these cases, and in the absence of a tuberculin test, IGRA
is recommended for obtaining a diagnosis of latent infec-
tion. In the case of unavailability of both tests, the decision
about TBLI treatment should be individualized, and the
physician will take into consideration its risks and beneﬁts.
When assessing the potential beneﬁt of this treatment, we
must consider the factors discussed (above) with respect to
the question of a positive epidemiology for tuberculosis. In
particular, the increased epidemiological risk (high disease
burden in the convivial environment) and the synergism of
risk factors for progression to TB disease should be evalu-
ated.
In the assessment of risk associated with treatment, we
must consider the hepatotoxic potential of isoniazid, espe-
cially in individuals aged >35 years, frequent alcohol users,
patients with previously abnormal liver function tests, and
in those individuals on concomitant use of other hepatotoxic
drugs. However, generally speaking, liver disease due to isoni-
azid is an uncommon occurrence, and the concomitant use of
hepatotoxic drugs is not an absolute contraindication to isoni-
azid use. However, the use of this agent requires liver function
test monitoring.
Finally, one must consider the potential for microbial resis-
tance induction, thanks to the indiscriminate use of isoniazid.
After the evaluation, if the treatment of TBLI is deemed unnec-
essary, a monthly clinical monitoring for early detection of
active TB is recommended, with special attention to signs such
as cough, fever, sweating and weight loss. The investigation
of symptomatic patients should be reﬁned to include at least
a radiographic study of chest, in addition to bacilloscopy and
sputum culture; and an expert evaluation (by a pulmonologist,
phthisiologist or infectologist) should also be considered.
The  performance  of  IGRA  for  diagnosing  TBLI  is
comparable  to  the  tuberculin  test?
The accuracy of IGRA is similar or superior to the tuberculin
skin test for diagnosis of TBLI. There is a potential advantage of
IGRA in BCG-vaccinated individuals and in immunodepressed
patients due to disease and/or treatment – situations where
the tuberculin test accuracy decreases due to false positives
and false negatives, respectively. There is debate about the
performance of IGRA in populations with high prevalence of
TB. There is also the possibility of indeterminate results, which
should be evaluated with caution; with such an occurrence, a
conduct of TBLI treatment should be considered. Despite such
considerations, given the current unavailability of the tuber-
culin skin test, the BSR advocates the incorporation of IGRA in
the list of procedures of the Brazilian Uniﬁed Health System
and supplementary health care.
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In  the  absence  of  TST,  and  with  availability  of  IGRA,  this
latter test  is  suitable  for  the  establishment  of  a  TBLI
diagnostic  in  all  patients  with  rheumatoid  arthritis  using
immunobiologicals?
Yes. IGRA is indicated in the same situations in which the
tuberculin skin test would apply, replacing it. Therefore, if
IGRA is available, its use is recommended for TBLI screening
in all patients with rheumatoid arthritis, when in use of an
TNF- inhibitor, in the absence of the tuberculin test. If there
is limited availability, we should prioritize IGRA for patients
with a negative or uncertain history of contact with a case of
pulmonary TB.
With  the  prolonged  use  of  a  TNF-˛  inhibitor,  or  with  an
exchange  of  biologicals  in  patients  who  completed
treatment  for  TBLI  in  the  past,  there  is  need  to  repeat  the
treatment  with  isoniazid?
As a rule, once treated fully and effectively, TBLI does not
require retreatment. Exceptions occur when there is a known
re-exposure to M. tuberculosis; in this case, retreatment is
indicated. Based on expert opinion, we  can consider a peri-
odic retreatment every 2 or 3 years in areas of high TB
prevalence, when a persistent state of immunodepression
prevails.11 However, a Brazilian study evaluated the efﬁcacy of
long-term TBLI screening and treatment in 202 patients with
rheumatoid arthritis in use of different TNF- inhibitors.13 In
this protocol, no regular retreatment for TBLI nor repetition
of the tuberculin skin test were carried out in asymptomatic
patients, and this conduct was continued for over 3 years of
follow-up.
Should  be  treated  for  TBLI  those  patients  with  respiratory
symptomatology  and  with  a  positive  history  of  contact
with  a  pulmonary  TB  case,  when  in  the  use  of  a  TNF-˛
inhibitor?
The prophylactic schemes are contraindicated, thanks to
the likelihood of TB disease emergence through inefﬁ-
ciency and/or potential microbial resistance induction. The
treatment of TBLI involves an active TB exclusion in all
instances. Contacts with respiratory symptomatology deserve
an extended investigation. In such cases, an assessment by a
TB specialist (pulmonologist, phthisiologist or infectologist),
with full treatment, when indicated, prior to the use of TNF-,
is recommended.
Once  the  possibility  of  TB  disease  was  ruled  out,  patients
with  a  history  of  contact  with  a  case  of
multidrug-resistant  TB  should  receive  treatment  for  TBLI,
when using  biological  DMARDs?
The treatment of TBLI in multidrug-resistant TB contacts
is not recommended. In symptomatic contacts, tuberculosis
should be investigated. In asymptomatic subjects, after rul-
ing out TB, a monthly clinical and half-yearly radiographic
follow-up is recommended in the ﬁrst two years. Isoniazid
prophylaxis should not be attempted. In such cases, the use of 0 1 5;5 5(4):390–393
a not-TNF-  inhibitor biological agent should be considered,
independently of the tuberculin skin test or IGRA.
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